All five patients who responded to the conjugate had high expression levels of MUC16 which underscores the importance of targeting strategies in increasing the effectiveness of cancer drugs by way of facilitating their efficient delivery to the tumor cells. The gene discussed is MUC16; the disease is neoplasm.